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A Trp-BODIPY cyclic peptide for fluorescence labelling of 
apoptotic bodies  
Ramon Subiros-Funosas,a,‡ Lorena Mendive-Tapia,b,‡ Jesus Sot,c John D. Pound,a Nicole Barth,a 
Yaiza Varela, c Felix M. Goñi,c Margaret Paterson,a Christopher D. Gregory,a Fernando Albericio,b,d 
Ian Dransfield,a Rodolfo Lavilla,d,e,* Marc Vendrella,* 
The rational design and synthesis of a Trp-BODIPY cyclic peptide 
for the fluorescent labelling of apoptotic bodies is described. 
Affinity assays, confocal microscopy and flow cytometry analysis 
confirmed the binding of the peptide to negatively-charged 
phospholipids associated with apoptosis, and its applicability for 
the detection and characterisation of subcellular structures 
released by apoptotic cells. 
Apoptosis is a process of programmed cell death taking place 
after severe cellular damage following specific signalling 
events. In early stages of apoptosis, molecules of 
phosphatidylserine (PS) are translocated to the outer face of 
the plasma membrane. Recent studies provide evidence that 
apoptotic cells release subcellular structures to the 
extracellular space in order to communicate with other cells.1-5 
These structures are membranous components that can be 
classified as exosomes, apoptotic vesicles and apoptotic 
bodies. Whereas exosomes, which range in size from 20-100 
nm, are secreted by multivesicular endosomes upon fusion 
with the plasma membrane, apoptotic vesicles (100-1000 nm) 
and apoptotic bodies (> 1000 nm) are expelled directly from 
the plasma membrane to the extracellular space. Although 
their precise mechanisms of action remain elusive, these 
structures play critical roles in many biological processes, such 
as coagulation, inflammation, tumour progression, cell 
adhesion or transfer of signalling components and genetic 
information. For instance, recent studies have validated 
tumour exosomes as important mediators in defining pre-
metastastic niches.6,7 As a result, subcellular vesicles secreted 
by apoptotic cells might become valuable biomarkers for 
monitoring and diagnosing several pathological conditions, 
which has prompted the development of novel methods for 
their detection and characterisation.8 One defining 
characteristic of apoptotic bodies is the presentation of 
negatively-charged phospholipids, such as PS, in high amounts. 
This feature has been exploited to design chemical reagents to 
monitor apoptosis in cells.9-11 Annexin V, a 36 kDa protein with 
high binding affinity to PS, has been widely used to monitor 
cell death in vitro.12 However, Annexin V-based labelling is 
limited by its high molecular weight, the formation of 
membrane lattices and its dependence on high concentrations 
of Ca2+, which are incompatible with many physiological 
environments. We envisaged that the development of probes 
for labelling apoptotic bodies in a Ca2+-independent manner 
would represent a significant advancement in the field. 
 
Figure 1 Chemical structures of peptide-based lactadherin mimics 
related to previous and the current work. 
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Scheme 1 Chemical synthetic approach for the solid-phase synthesis of the cLac-BODIPY.  
Lactadherin is a β sheet-rich glycoprotein (43 kDa) that acts as 
a bridge between phagocytic receptors (e.g. V5) and 
apoptotic cells by binding at externalised PS in a Ca2+-
independent manner. Based on the disposition of lactadherin 
residues upon binding to PS, Zheng and co-workers condensed 
its fundamental amino acids to prepare lactadherin-like small 
cyclic peptides (cLac-1, Fig 1).13 We envisioned that fluorescent 
probes of the cLac family might be useful tools for labelling PS-
rich apoptotic bodies, given their high sensitivity and suitability 
for imaging assays.14-15 However, most labelling methods alter 
the molecular properties of small peptides. Our group has 
optimized C-H activation methodologies16-19 and pioneered the 
Trp-BODIPY fluorogenic amino acid for non-perturbative 
labelling of peptide sequences.20 The Trp-BODIPY amino acid 
emits fluorescence once labelled peptides bind to their 
corresponding targets, which leads to the rigidification and 
fluorescence enhancement of the Trp-BODIPY fluorophore 
(Figure S1 in Electronic Supplementary Information).20 Since 
the cLac-1 peptide contains one Trp in its original sequence, 
we prepared a fluorescent cyclic peptide (cLac-BODIPY) for 
binding to PS-rich vesicles by replacing the Trp of cLac-1 with 
the Trp-BODIPY amino acid (Fig 1). Using this approach, we 
examined cLac-BODIPY as a novel probe to fluorescently label 
apoptotic bodies in a Ca2+-independent manner.  
 
We designed the synthesis of cLac-BODIPY in solid-phase by 
selecting appropriate orthogonal protecting groups and using 
2-chlorotritylchloride polystyrene resin as the solid support, in 
order to cleave the peptide under mild acidic conditions 
without affecting the BODIPY core (Scheme 1).21,22 We used 
Mmt as the protective group for His and the NO2 group for Arg 
because they can be removed by mild acidic treatment and 
hydrogenation respectively,23 and Gln was introduced without 
any side-chain protection. Furthermore, in order to maximize 
the efficiency of the cyclisation, we designed a head-to-tail 
solid-phase approach by anchoring the peptide through the 
side chain of the Asp residue, while protecting the C-terminal 
carboxylic acid as an allylic ester. The peptide elongation was 
performed using standard conditions,24-26 followed by on-bead 
cyclisation. The partially-protected peptide was isolated after 
treatment with TFA: DCM (1: 99), and cLac-BODIPY was 
obtained in very high purities (> 99 %) after catalytic 
hydrogenation and reverse-phase HPLC purification (Figures 
S2-S3 in ESI).  
 
In order to assess the properties of cLac-BODIPY and its 
affinity for PS, we measured the fluorescence spectra of cLac-
BODIPY upon incubation with layers of constant lipid content 
and different ratios of PS and phosphatidylcholine (PC). As 
shown in Figure 2, cLac-BODIPY displayed a dose-dependent 
increase of the fluorescence emission after interaction with PS, 
with low emission in films containing only PC. 
 
Figure 2 a) Fluorescence spectra of cLac-BODIPY in films with constant lipid 
content and increasing PS: PC ratios. QY (100% PS): 0.46, QY (100% PC): 
0.08. b) Fluorescence emission of cLac-BODIPY under 365 nm in solutions 
with different PS: PC ratios and PBS as a blank. c) Ca2+-independent binding 
between cLac-BODIPY and PS ([CaCl2]: 2 mM, [EDTA]: 2.5 mM). *** for p < 
0.001, ns for p > 0.05. 
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cLac-BODIPY showed a remarkable fluorescence quantum 
yield upon binding to PS (0.46) due to the fluorogenic 
behaviour of the Trp-BODIPY reporter. Furthermore, we 
assessed the fluorescence emission of cLac-BODIPY after 
incubation with PS-containing lipid layers in the presence and 
absence of Ca2+. Unlike Annexin V, the interaction between 
cLac-BODIPY and PS did not show any dependence on Ca2+, 
which confirms the applicability of cLac-BODIPY to recognise 
PS-rich vesicles under most physiological conditions (Figure 2 
and Figure S4 in ESI).   
 
In view of the excellent features of cLac-BODIPY as a 
fluorescent reporter for PS-rich environments, we examined its 
physicochemical properties in lipid-aqueous interfaces. First, 
we determined the tensioactive potential of cLac-BODIPY by 
measuring the surface pressure of lipid-aqueous mixtures at 
different concentrations of the probe. cLac-BODIPY displayed 
remarkable tensioactivity and was able to form monolayers in 
the air-water interphase with a saturation pressure (πs) of 20.4 
mN m-1 (Table 1 and Fig S5 in ESI). We compared the 
behaviour of cLac-BODIPY with the non-labelled peptide cLac-
1 under the same experimental conditions, and observed that 
cLac-BODIPY displayed significantly stronger tensioactivity (Fig 
S5 in ESI), suggesting its suitability to monitor biomolecular 
changes in these interphases. These results also confirm that 
the BODIPY fluorophore is an optimal scaffold for reporting 
molecular events associated with lipid-rich environments.27-29 
 
Table 1 Critical surface pressure quantification assays in lipid monolayers. 
 a Relative decrease in πc values when comparing PC:PS (7:3) 
monolayers (PS) to PC monolayers (PC) or PC:PG (7:3) monolayers (PG: 
phosphatidylglycine). 
 
Next we quantified the binding affinity of cLac-BODIPY for 
different phospholipids by determining the critical surface 
pressure of cLac-BODIPY in lipid monolayers with different 
composition. cLac-BODIPY incorporated into PS-containing 
monolayers (PC: PS, 7: 3) with a critical pressure of 42 mN m-1, 
with 15% lower affinity (36 mM m-1) in PC-only monolayers 
(Table 1 and Fig S6 in ESI). We extended the analysis to other 
negatively-charged phospholipids (e.g. phosphatidylglycine 
(PG), cardiolipin) that are associated with apoptotic 
processes,30 and observed the increased binding of cLac-
BODIPY for monolayers containing these lipids over PC-only 
monolayers (Figures S7 in ESI). This pattern suggests the 
preferential binding of cLac-BODIPY to labelling subcellular 
structures derived from apoptotic cells. We also examined the 
specificity of these interactions by analysing the behaviour of 
the non-labelled peptide cLac-1. Notably, the relative binding 
pattern of cLac-1 to the different phospholipids closely 
correlated with that observed for cLac-BODIPY (Table 1 and 
Figure S7 in ESI). This minimal impairment in the lipid 
recognition ability of the cLac-1 peptide indicates that the 
BODIPY fluorogen is optimally positioned within the cLac 
peptide sequence. Altogether, these results confirm the 
preferential binding of cLac-BODIPY to lipid domains found in 
structures released by apoptotic cells. 
 
We employed cLac-BODIPY in fluorescence microscopy 
experiments with PS-containing vesicles as well as other 
lipidated vesicles. We prepared giant unilamellar vesicles 
(GUVs) containing PC-only or PC: PS (7: 3), and incubated them 
with the same concentration of cLac-BODIPY and lissamine-
rhodamine-PE as a generic lipid stain. As shown in Figure 3, 
cLac-BODIPY displayed significantly brighter staining in vesicles 
containing PC: PS (7: 3) than in vesicles with only PC. This 
observation is in agreement with our results from the in vitro 
assays in lipid monolayers and confirms the applicability of 
cLac-BODIPY for the fluorescence labelling of apoptotic bodies.  
 
 
Figure 3 Confocal fluorescence microscopy images of giant unilamellar 
vesicles (GUVs) containing PC-only or PC: PS (7: 3) after co-staining 
with lissamine-rhodamine-PE (red, lipid stain) and cLac-BODIPY (green, 
2 M). White and yellow arrows point at vesicles of similar size in PC 
only and PC: PS (7: 3) GUVs. Scale bar: 10 m. 
Finally, we examined cLac-BODIPY as a fluorescent probe for 
labelling subcellular structures derived from apoptotic human 
cells. We induced apoptosis in Burkitt’s lymphoma (BL2) cells 
by irradiation with UV light and subsequent culture, and 
isolated the apoptotic bodies. First we incubated the apoptotic 
bodies with different concentrations of cLac-BODIPY and 
analysed the fluorescence labelling by flow cytometry (Figures 
4a and b). cLac-BODIPY showed dose-dependent staining, with 
significant labelling even at low concentrations (Figure S8 in 
ESI). Flow cytometry assays confirmed that most apoptotic 
bodies stained with cLac-BODIPY were also stained with 
Annexin V, suggesting the interaction with PS as the 
responsible for the fluorescence labelling of apoptotic bodies 
using cLac-BODIPY (Figure 4c). Furthermore, we employed 
 πs (mN m-1) πc (mN m-1) Decrease πc vs PS a 
  PS PC PG 
cLac-BODIPY 20.4 42.0 15% <1% 
cLac-1 5.0 30.3 16% <1% 
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fluorescence microscopy to visualize subcellular bodies derived 
from apoptotic human A549 cells (Figure S9 in ESI). 
 
Figure 4 Flow cytometry analysis of apoptotic bodies from BL2 cells. 
Histograms of apoptotic bodies incubated without (a) and with cLac-BODIPY 
(2.5 M) (b). c) Dot plot of apoptotic bodies treated with cLac-BODIPY (X-
axis, green) and Annexin V-PE (Y-axis) showing the double staining. 
 
In summary, we have synthesized a fluorescent cyclic peptide 
(cLac-BODIPY) to label apoptotic bodies by including the 
fluorogenic Trp-BODIPY amino acid into a short lactadherin-
like peptide sequence. cLac-BODIPY shows remarkable 
fluorescence emission only after binding to phosphatidylserine 
and, unlike Annexin V, displays strong binding in a Ca2+ 
independent-manner. In vitro assays in lipid monolayers 
indicate the suitability of the Trp-BODIPY fluorogen to report 
changes in the composition of lipid-aqueous interphases, and 
validated the selectivity of cLac-BODIPY for PS-rich vesicles 
using fluorescence confocal microscopy. Flow cytometry 
experiments using cLac-BODIPY confirmed the labelling of 
apoptotic bodies from BL2 human lymphoma cells, creating 
new opportunities to monitor, profile and characterise these 
subcellular structures in multiple biological contexts. 
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